Pfizer's (NYSE:PFE) stock is up by a considerable 7.5% over the past month. However, we decided to pay attention to ...

Pfizer Inc. (NYSE:PFE) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Analyst Asad Haider of Goldman ...

Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

The recent experience of Chinese biotech companies in developing their own drug candidates and inking deals with larger ...

Pfizer (NYSE:PFE) recently ended its strategic collaboration with Acepodia and is facing legal challenges related to Depo-Provera, reflecting significant changes that provide a backdrop of strategic ...

Dividend stocks can set you up for life. But, making the right choice will determine whether you enjoy a steady income or ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since 2022 is largely due to its coronavirus portfolio.

Based on Pfizer’s latest earnings release for the quarter ending March 29, the company reported a quarterly revenue of $13.72 billion and a net profit of $2.97 billion. In comparison, last year the ...

Pfizer: Where's The Growth Catalyst? If you're a Pfizer Inc. (NYSE:PFE) investor, you have to really ask yourself whether it’s still worthwhile to stay on for the “grind,” as multitudinous ...

Pfizer (NYSE:PFE) said on Friday that a late-stage trial evaluating a Braftovi combination increased survival time for patients with metastatic colorectal cancer with a BRAF V600E mutation.

Bernstein analyst Justin Smith maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The company’s shares closed yesterday at ...